Methylated spirits: Epigenetic hypotheses of psychiatric disorders

CNS Spectrums

Volumn 15, Issue 4, 2010, Pages 220-230

  Stahl, Stephen M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; CATECHOL METHYLTRANSFERASE; DOPAMINE; GLUTAMIC ACID;

ARTICLE; DNA METHYLATION; DNA SEQUENCE; ENVIRONMENTAL FACTOR; EPIGENETICS; GENE ACTIVATION; GENE SILENCING; MENTAL DISEASE; MOLECULAR MECHANICS; PRIORITY JOURNAL; PSYCHOPHARMACOLOGY; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

EID: 77952580118     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900000055     Document Type: Article

References (61)

1. Waddington CH. The Strategy of the Genes. New York, NY: MacMillan; 1957.
2. Nestler EJ. Epigenetic mechanisms in psychiatry. Biol Psychiatry. 2009;65:189-190.
3. Stahl SM. Epigenetics and methylomics in psychiatry. J Clin Psychiatry. 2009;70:1204-1205.
4. Sweatt JD. Experience-dependent epigenetic modifications in the central nervous system. Biol Psychiatry. 2009;65:191-197.
5. Slack A, Cervoni N, Pinard M, Szyf M. Feedback regulation of DNA methyltransferase gene expression by methylation. Eur J Biochem. 1999;264:191-199.
6. Jamaluddin Md S, Chen I, et al. Homocysteine inhibits endothelial cell growth via DNA hypomethylation of the cyclin A gene. Blood. 2007;110: 3648-3655.
7. Wainfan E, Poirier LA. Methyl groups in carcinogenesis: effects on DNA methylation and gene expression. Cancer Res. 1992;52(7 suppl):2071S-2077S.
8. Szyf M. DNA methylation and demethylation as targets for anticancer therapy. Biochemistry (Mosc). 2005;70:533-549.
9. Stahl SM. Stahls Essential Psychopharmacology, 3rd edition. New York, NY: Cambridge University Press; 2008.
10. Stahl SM. Fooling Mother Nature: epigenetics and novel treatments for psychiatric disorders. CNS Spectr. In Press.
11. Friso S, Choi S-W. Gene-nutrient interactions in one-carbon metabolism. Curr Drug Metab. 2005;6:37-46.
12. Friso S, Choi S-W. Gene-nutrient interactions and DNA methylation. J Nutr. 2002;132:2382S-2387S.
13. Stahl SM. Novel Therapeutics for Depression: L-methylfolate (6 (S)-5 methyltetrahydrofolate or MTHF) as a trimonoamine modulator and antidepressant augmenting agent. CNS Spectr. 2007;12:423-428.
14. Akbarian S, Huang H-S. Epigenetic regulation in human brain: focus on histone lysine methylation. Biol Psychiatry. 2009;65:198-203.
15. Monteggia LM, Kavalali ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry. 2009;65:204-210.
16. Cohen SM, Nichols A, Wyatt R, Pollin W. The administration of methionine to chronic schizophrenia patients: a review of 10 studies. Biol Psychiatry. 1974;8:209-225.
17. Abdolmaleky HM, Cheng KH, Faraone SV, et al. Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Hum Mol Genet. 2006;15:3132-3145.
18. Abdolmaleky HM, Smith CL, Zhou RJ, Thiagalingam S. Epigenetic alterations of dopaminergic system in major psychiatric disorders. In: Yan Q, ed. Pharmacogenomics in Drug Discovery and Development. New York, NY: Humana Press; 2008:187-212.
19. Veldic M, Caruncho JH, Liu WS, et al. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons on schizophrenia brains Proc Natl Acad Sci. 2004;101:348-353.
20. Costa E, Dong E, Grayson DR, Guidotti A, Ruzicka W, Veldic M. Reviewing the role of DNA (Cytosine-5) methyltransferase overexpression in the cortical GABAergic dysfunction associated with psychosis vulnerability. Epigenetics. 2007;2:29-36.
21. Veldic M, Kadriu B, Maloku E, et al. Epigenetic mechanisms expressed in basal ganglia GABAergic neurons differentiate schizophrenia from bipolar disorder. Schizophr Res. 2007;91:51-61.
22. Tremolizzo L, Caraboni G, Ruzicka WB, et al. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci. 2002;99:17095-17100.
23. Abdolmaleky HM, Cheng KH, Russo A, et al. Hypermethylation of the Reelin RELN promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet B Neuropsychiatr Genet. 2005;134:60-66.
24. Abdolmaleky HM, Smith CL, Zhou J-R, Thiagalingam S. Epigenetic modulation of reelin function in schizophrenia and bipolar disorder. In: SH Fatem, ed. Reelin Glycoprotein: Structure, Biology and Roles in Health and Disease. New York, NY: Springer; 2008:365-384.
25. Noh JS, Sharma RP, Veldic M, et al. DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc Natl Acad Sci. 2005;102:1749-1754.
26. Grayson DR, Jia X, Chen Y, et al. Reelin promoter hypermethylation in schizophrenia. Proc Natl Acad Sci. 2005;102:9341-9346.
27. Mill J, Tang T, Kaminsky Z, et al. Epigenomic profiling reveals DNA methylation changes associated with major psychosis. Am J Human Genet. 2008;82:696-711.
28. Murphy BC, O'Reilly RL, Singh SM. Site specific cytosine methylation in S-COMT promoter in 31 brain regions with implications for studies involving schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2005;133:37-42.
29. Tochigi M, IwamotoK, Bundo M, et al. Methylation status of the reelin promoter region in the brain of schizophrenic patients. Biol Psychiatry. 2008;63: 530-533.
30. Abdolmaleky HM, Smith CL, Farone SV, et al. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet B Neuropsychiatr Genet. 2004;127B:51-59.
31. Stadler F, Kolb G, Bubusch L, Baker SP, Jones EG, Akbarian S. Histone methylation at gene promoters is associated with developmental regulation and region-specific expression of ionotropic and metabotropic glutamate receptors in human brain. J Neurochem. 2005;94:324-336.
32. Huang HS, Matevossian A, Whittle C, et al. Prefrontal dysfunction in schizophrenia involves mixed-lineage leukemia 1-regulated histone methylation at GABAergic gene promoters. J Neurosci. 2007;27:11254-11262.
33. Shimabukuro M, Sasaki T, Imamura A, et al. Global hypomethylation of peripheral leukocyte DNA in male patients with schizophrenia: a potential link between epigenetics and schizophrenia. J Psychiatr Res. 2007;41:1042-1046.
34. Connor CM, Akbarian S. DNA methylation changes in schizophrenia and bipolar disorder. Epigenetics. 2008;3:55-58.
35. Freeman JM, Finkelstein JM, Mudd SH. Folate-responsive homocysteinuria and "schizophrenia." A defect in methylation due to deficient 5,10-methylenetetrahydrofolate reductase activity. N Eng J Med. 1975;292:491-496.
36. Fiso S, Choi S-W, Girelli D, et al. A common mutation in the 5,10-methylenetetrahydrofolate reductase gene affects genomic DNA methylation through an interaction with folate status, Proc Natl Acad Sci. 2002;99:5606-5611.
37. Gilbody S, Lewis S, Lightfoot T. Methylenetetrahydrofolate reductase (MTHFR) genetic polymorphisms and psychiatric disorders: A HuGE Review. Am J Epidemiol. 2007;165:1-13.
38. Goff DC, Bottiglieri T, Arning E, et al. Folate, homocysteine and negative symptoms of schizophrenia. Am J Psychiatry. 2004;161:1705-1708.
39. Godfrey PSA, Toone BK, Carney MWB, et al. Enhancement of recovery from psychiatric illness by methylfolate. Lancet. 1990;336:392-395.
40. Levine J, Stahl Z, Sela B-A, et al. Homocysteine-reducing strategies improve symptoms in chronic schizophrenic patients with hyperhomocysteinemia. Biol Psychiatry. 2006;60:265-269.
41. Roffman JL, Weiss AP, Deckersbach T, et al. Effects of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism on executive function in schizophrenia. Schizophr Res. 2007;92:181-188.
42. Roffman JL, Weiss AP, Purcell S, et al. Contribution of methylenetetrahydrofolate reductase (MTHFR) polymorphisms to negative symptoms in schizophrenia. Biol Psychiatry. 2008;63:42-48.
43. Muntjewerff J-W, Gellekink H, den Heijer M, et al. Polymorphisms in catechol-O-methyltransferase and methylenetetrahydrofolate reductase in relation to the risk of schizophrenia. Eur Neuropsychopharmacol. 2008;18:99-106.
44. Muntjewerff JW, Kahn RS, Blom HJ, den Heijer M. Homocysteine, methylenetetrahydrofolate reductase and risk of schizophrenia: a meta analysis. Mol Psychiatr. 2006;11:143-149.
45. Lewis SJ, Zammit S, Gunnell D, Smith, GD. A meta analysis of the MTHFR C677T polymorphism and schizophrenia risk, Am J Med Genetics Part B. Neuropsychiatric Genetics. 2005;135B:2-4.
46. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet B Neuropsychiatr Genet. 1997;74:526-528.
47. Roffman JL, Gollub RL, Calhoun VD, et al. MTHFR 677C to T genotype disrupts prefrontal function in schizophrenia through an interactions with COMT 158 val to met. Proc Natl Acad Sci. 2008;105:17573-17578.
48. Roffman JL, Weiss AP, Decersbach T, et al. Interactive effects of COMT val108/158Met and MTHFR C677T on executive function in schizophrenia. Am J Med Genet B Neuropsychiatr Genet. 2008;147B:990-995.
49. Kempisty B, Skiora J, Lianeri M, et al. MTHFD 1958G>A and MTR 2756A>G polymorphisms are associated with bipolar disorder and schizophrenia. Psychiatr Genet. 2007;17:177-181.
50. Picker JD, Coyle JT. Do maternal folate and homocysteine levels play a role in neurodevelopmental processes that increase risk for schizophrenia? Harvard Rev Psychiatry. 2005;13:197-205.
51. Brown AD, Susser ES. Prenatal nutritional deficiency and risk of adult schizophrenia. Schiz Bull. 2008;34:1054-1063.
52. Brown AS, Bottiglieri T, Schaefer CA, et al. Elevated prenatal homocysteine levels as a risk factor for schizophrenia. Arch Gen Psychiatry. 2007;64:31-39.
53. Jiang Y, Sun T, Xiong J, Cao J, Li G, Wang S. Hyperhomocysteinemia-mediated DNA hypomethylation and its potential epigenetic role in rats. Acta Biochim Biophys Sin (Shanghai). 2007;39:657-667.
54. Fan G, Beard C, Chen RZ, et al. DNA hypomethylation perturbs the function and survival of CNS neurons in postnatal animals. J Neurosci. 2001;21:788-797.
55. Ingrosso D, Cimmino A, Perna AF, et al. Folate treatment and unbalanced methylation and changes of allelic expression induced by hyperhomocyseinemia in patients with uraemia. Lancet. 2003;361:1693-1699.
56. Obeid R, McCaddon A, HerrmannW. The role of hyperhomocysteinemia and B-vitamin deficiency in neurological and psychiatric diseases. Clin Chem Lab Med. 2007;45:1590-1606.
57. Blount BC, Mack MM, Wehr CM, et al. Folate deficiency causes uracil misincorporation into DNA and chromosome breakage: implications for cancer and neuronal damage. Proc Natl Acad Sci. 1997;94:3290-3295.
58. Nagothu KK, Rishi AK, Jaszewski R, Kucuk O, Najumdar APN. Folic acid-mediated inhibition of serum-induced activation of EGFR promoter in colon cancer cells. Am J Phusiol Gastrointest Liver Physiol. 2004;287:G541-G546.
59. Henning SM, Swendseid ME, Coulson WF. Male rats fed methyl- and folate-deficient diets with or without niacin develop hepatic carcinomas associated with decreased tissue NAD concentrations and altered poly (ADP-ribose) polymerase activity. J Nutr. 1997;127:30-36.
60. Pogribny IP, James SJ. De Novo methylation of the;16INK4A gene in early preneoplastic liver and tumors induced by folate/methyl deficiency in rats. Cancer Lett. 2002;187:69-75.
61. Pogribny IP, Poirier LA, James SJ. Differential sensitivity to loss of cytosine methyl groups within the hepatic p53 gene of folate/methyl deficient rats. Carcinogenesis. 1995;16:2863-2867.